×
About 4,470 results

ALLMedicine™ Epistaxis Center

Research & Reviews  1,382 results

A case of hereditary hemorrhagic telangiectasia and literature review.
https://doi.org/10.1002/jcla.24571
Journal of Clinical Laboratory Analysis; Han Y, Ding B et. al.

Jun 28th, 2022 - To discuss the clinical features of a patient with hereditary hemorrhagic telangiectasia (HHT). The clinical data of one patient with HHT are retrospectively analysed. In addition, we review the relevant literature. A 32-year-old male patient was ...

Intranasal Topical Application of Tranexamic Acid in Atraumatic Anterior Epistaxis: A D...
https://doi.org/10.1016/j.annemergmed.2022.04.010
Annals of Emergency Medicine; Hosseinialhashemi M, Jahangiri R et. al.

Jun 26th, 2022 - To determine the effectiveness of intranasal topical application of tranexamic acid in reducing the need for anterior nasal packing and determine the number of episodes of rebleeding in adult patients presenting with spontaneous atraumatic anterio...

Periodontal treatment of patients with hereditary hemorrhagic telangiectasia.
https://www.ncbi.nlm.nih.gov/pubmed/35749250
General Dentistry; de Paiva Gonçalves V, Onofre MA et. al.

Jun 25th, 2022 - Hereditary hemorrhagic telangiectasia (HHT) is a rare condition in which fragile vascular walls lead to increased risks of bleeding, cerebral abscesses, arteriovenous malformations, anemia, and thrombosis. To date, no protocol has been established...

A Natural History Study of Children and Adults With Olfactory Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04755205

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 ...

Myelodysplastic Syndrome (MDS) Clinical Presentation
https://emedicine.medscape.com/article/207347-clinical

Jun 23rd, 2022 - History The development of myelodysplastic syndrome (MDS) may be preceded by a few years by an unexplained macrocytic anemia with no evidence of megaloblastic anemia and a mild thrombocytopenia or neutropenia. Clinical symptoms that should prompt ...

see more →

Guidelines  1 results

Clinical Practice Guideline: Nosebleed (Epistaxis).
https://doi.org/10.1177/0194599819890327
Otolaryngology--head and Neck Surgery : Official Journal ... Tunkel DE, Anne S et. al.

Jan 8th, 2020 - Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds w...

see more →

Drugs  165 results see all →

Clinicaltrials.gov  111 results

A Natural History Study of Children and Adults With Olfactory Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04755205

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 ...

Post-operative Pain Control With Acetaminophen and Ibuprofen After Functional Endoscopic Sinus Surgery
https://clinicaltrials.gov/ct2/show/NCT05287217

Jun 22nd, 2022 - The safest and most effective post-operative pain control regimen after functional endoscopic sinus surgery (FESS) has been the subject of persistent debate and research for many years. The main reasons for this debate is due to two factors: 1) en...

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
https://clinicaltrials.gov/ct2/show/NCT04113187

Jun 14th, 2022 - Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic autosomal dominantly inherited disorder of angiogenesis. Its major feature is the occurrence in 90% of patients of spontaneous and recurrent epistaxis responsible for iron deficiency a...

Sirolimus for Nosebleeds in HHT
https://clinicaltrials.gov/ct2/show/NCT05269849

Jun 2nd, 2022 - The most common symptom of the hereditary hemorrhagic telangiectasia (HHT) disease is epistaxis. HHT is characterized by vascular (blood vessel) malformations, of the skin and mucus membranes of the nose (telangiectasia), gastrointestinal track, b...

Controlled Sedoanalgesia in External DCR Surgery
https://clinicaltrials.gov/ct2/show/NCT05397301

May 31st, 2022 - The patients were routinely monitored in the operating room in accordance with the standard protocol for elective surgeries, and the preoperative findings (blood pressure, oxygen saturation, cardiac rhythm, peak heart rate) were recorded. The deci...

see more →

News  128 results

Skull Base Regeneration During Treatment With Chemoradiation for Nasopharyngeal Carcinoma: A Case Report
https://www.mdedge.com/fedprac/avaho/article/254501/head-neck/thyroid-cancers/skull-base-regeneration-during-treatment
Kelly F. Moyer, MD, Jessica H. Maxwell, MD, MPH et. al.

May 10th, 2022 - Nasopharyngeal carcinoma (NPC) differs from other head and neck (H&N) cancers in its epidemiology and treatment. Unlike other H&N cancers, NPC has a distinct geographical distribution with a much higher incidence in endemic areas, such as southern.

Ceralasertib Plus Acalabrutinib Shows Early Activity in High-Risk Relapsed/Refractory CLL
https://www.onclive.com/view/ceralasertib-plus-acalabrutinib-shows-early-activity-in-high-risk-relapsed-refractory-cll

Apr 29th, 2022 - The combination of ceralasertib (AZD6738) and acalabrutinib (Calquence) showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), according to data from a ...

FDA Grants Fast Track Status to HPN217 for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-fast-track-status-to-hpn217-for-relapsed-refractory-multiple-myeloma

Mar 3rd, 2022 - The FDA has granted a fast track designation to the BCMA-targeting Tri-specific T-cell Activating Construct (TriTAC), HPN217, for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who have previously re...

Lower Leg Hyperpigmentation in MYH9-Related Disorder
https://www.mdedge.com/dermatology/article/251390/pigmentation-disorders/lower-leg-hyperpigmentation-myh9-related-disorder
Ashley N. Elsensohn, MD, MPH, Logan William Thomas, MD et. al.

Feb 3rd, 2022 - To the Editor: MYH9-related disorder is an autosomal-dominant disorder characterized by macrothrombocytopenia and neutrophil inclusions secondary to defective myosin-9. 1 We describe a case of lower leg hyperpigmentation secondary to hemosiderin de.

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies
https://www.onclive.com/view/cervical-cancer-treatment-paradigm-is-bolstered-with-newly-approved-therapies

Jan 28th, 2022 - Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival (OS) rate is just 17%.1 Whereas many other solid tumors have seen a plethora of FDA approvals of clinically meaningful treatments, there has been...

see more →

Patient Education  1 results see all →